<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: Pleiotrophin (PTN) is an important developmental secretory cytokine expressed in many types of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> and involved in <z:mpath ids='MPATH_177'>angiogenesis</z:mpath> and <z:e sem="disease" ids="C0598934" disease_type="Neoplastic Process" abbrv="">tumor growth</z:e>; however, the significance of PTN expression in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) has not been established </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: Immunohistochemistry, western blot, and enzyme-linked immunosorbent assay were used to detect PTN expression in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> patients </plain></SENT>
<SENT sid="2" pm="."><plain>The relationship between PTN expression and clinicopathological characteristics and survival time was statistically analyzed, and the relationship between PTN and vascular endothelial growth factor (VEGF) in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> <z:mpath ids='MPATH_177'>angiogenesis</z:mpath> was further analyzed </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: Of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> tissues, 74.70% (62/83) stained positive, with a strong positive ratio of 60.24% (50/83) </plain></SENT>
<SENT sid="4" pm="."><plain>The expression of PTN in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> tissues was much higher than in <z:mpath ids='MPATH_458'>normal</z:mpath> colorectal tissues </plain></SENT>
<SENT sid="5" pm="."><plain>PTN serum levels in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> patients (mean = 254.59 ± 261.76 pg/ml) were significantly higher than those of <z:mpath ids='MPATH_458'>normal</z:mpath> volunteers (mean = 115.23 ± 79.53 pg/ml; p &lt; 0.001) </plain></SENT>
<SENT sid="6" pm="."><plain>PTN expression was related to <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> differentiation and TNM staging </plain></SENT>
<SENT sid="7" pm="."><plain>High level of PTN is a predictor of a poor prognosis and high expression of PTN is accompanied by high expression of VEGF in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> patients </plain></SENT>
<SENT sid="8" pm="."><plain>Investigation of the relationship between PTN and VEGF revealed that PTN, through the PTN/RPTPβ/ζ signaling pathway, increased tyrosine phosphorylation of β-catenin, leading to an increase in VEGF </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: Our study identifies PTN as an essential growth factor for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
<SENT sid="10" pm="."><plain>PTN promotes VEGF expression and cooperates with VEGF in promoting <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> <z:mpath ids='MPATH_177'>angiogenesis</z:mpath> </plain></SENT>
<SENT sid="11" pm="."><plain>PTN could serve as a prognostic factor for this <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> </plain></SENT>
<SENT sid="12" pm="."><plain>Considering that PTN shows very limited expression in <z:mpath ids='MPATH_458'>normal</z:mpath> tissue, it may represent an attractive new target for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> therapy </plain></SENT>
</text></document>